BC
SYRE icon

Bayforest Capital’s Spyre Therapeutics SYRE Stock Holding History

Bayforest Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
+2,305
New +$168K 0.19% 167

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bayforest Capital's SYRE Position: Q2 2026 in Review

Bayforest Capital opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 2,305 shares worth $205K. The stake represents 0.19% of the portfolio and ranks #167 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Bayforest Capital held 2,305 shares of Spyre Therapeutics worth $205K as of Q2 2026.
  • Spyre Therapeutics was a new Bayforest Capital position in Q2 2026.
  • Spyre Therapeutics made up 0.19% of Bayforest Capital's portfolio in Q2 2026, its #167 holding.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.